Loading…
XRTX
XORTX Therapeutics Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 98420Q405
$2.34-4.38%Price as of Aug 29, 18:48 UTC · updated once a day, after the close
Key metrics
- Market cap
- $4.25M
- P/E
- —
- Forward P/E
- 2.9x
- P/B
- 1.6x
- Dividend yield
- —
- Payout
- —
- EPS
- -$2.47
- ROE
- -99.24%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.08
- 52-week high
- $7.05
- 52-week low
- $1.73
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.9% over 5Y.
today you would have $0.87▼ -99.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $2.81 | $5.65 | $11.55 | $327.24 | |
| P/B | 1.5x | 1.9x | 1.2x | 1.0x | 15.6x |
| EPS | -$2.80 | -$5.75 | -$5.45 | -$23.54 | |
| ROE | -104.81% | -127.43% | -99.30% | -46.49% | -110.32% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| APVOAptevo Therapeutics Inc. | $2.37 | 0.0x | 0.6x | — | -420.34% | $4.26M |
| GRIGRI Bio, Inc. | $1.92 | — | 0.4x | — | -142.02% | $4.2M |
| ELABPMGC Holdings Inc. | $5.31 | — | 0.2x | — | -105.22% | $4.3M |
| JAGXJaguar Health, Inc. | $0.81 |
About the company
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
- Calgary, Canada
Company description provided by Yahoo Finance.